Stevanato Group(US:STVN)2025-11-06 13:30Financial Performance - Revenue grew by 9% year-over-year (11% at constant currency) in Q3 2025, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment[12] - High-Value Solutions (HVS) revenue increased by 47% year-over-year, reaching €147.9 million, representing 49% of total revenue[28] - Adjusted EBITDA increased to €77.8 million, with an adjusted EBITDA margin increase of 280 bps to 25.7%[29] - The company maintains its fiscal year 2025 revenue guidance at €1.160 billion - €1.190 billion, implying a growth of 5% to 8%[39] Segment Analysis - The BDS segment revenue increased by 14% (17% at constant currency), with a gross profit margin increase of 400 bps to 32.0%[32] - The Engineering segment revenue decreased by 19% to €36.4 million, with a gross profit margin decrease to 10.4%[34] Capacity Expansion and Investments - The company is expanding capacity for PFS and EZ-fill® cartridges in Latina, Italy, with commercial production expected to launch at the end of FY26[22] - Capital expenditures (CAPEX) for Q3 2025 were €54.9 million[36]